Table 1 The systemic parameters and univariate analysis of these parameters on logarithm transformed ocular staining score
From: Factors associated with ocular surface epithelial damage in patients with primary Sjögren’s syndrome
Variables | DED related to pSS (n=82) | Univariate analysis | |
|---|---|---|---|
Beta (SE) | P-value | ||
Age (y) | 53.8 ± 11.2 (24-80) | 0.009 (0.006) | 0.136 |
Sex, n (%) | |||
Male | 4 (4.9%) | 1 (Ref) | |
Female | 78 (95.1%) | 0.005 (0.309) | 0.988 |
Duration of disease (m) | 39.4 ± 45.4 (1-185) | 0.003 (0.001) | 0.029 |
Systemic disease, n (%) | |||
No history | 61 (74.4%) | 1 (Ref) | |
Hypertension | 16 (19.5%) | 0.144 (0.167) | 0.389 |
Diabetes mellitus | 3 (3.7%) | 0.250 (0.353) | 0.482 |
Ocular surgery history, n (%) | |||
No history | 69 (84.1%) | 1 (Ref) | |
Refractive surgery | 6 (7.3%) | -0.356 (0.252) | 0.162 |
Pharmacological history, n (%) | |||
Oral Pilocarpine | 16 (19.5%) | -0.024 (0.134) | 0.857 |
Oral Hydroxychloroquine | 3 (3.7%) | -0.134 (0.147) | 0.365 |
Oral Methotrexate | 15 (18.3%) | -0.029 (0.172) | 0.864 |
Oral Cyclosporine | 3 (3.7%) | 0.413 (0.351) | 0.243 |
Oral Steroid | 14 (17.1%) | 0.204 (0.175) | 0.246 |
Topical Cyclosporine | 3 (3.7%) | 0.551 (0.185) | 0.004 |
Topical Steroid | 11 (13.4%) | 0.218 (0.175) | 0.217 |